Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by PoorOpinionon Oct 15, 2018 4:46pm
105 Views
Post# 28805200

RE:RE:RE:RE:RE:RE:RE:RE:From CIBC March 2018 report

RE:RE:RE:RE:RE:RE:RE:RE:From CIBC March 2018 report
palinc2000 wrote: https://www.stockhouse.com/companies/bullboard/t.th/theratechnologies-inc?postid=28013163


Maybe your problem here is trusting jfm to provide fully accurate info.

This website seems to allow us to read the full Les Affaires article, but its in French, so a full Francophone would help (I'm not).

https://www.pressreader.com/canada/les-affaires/20180512/282321090646034

There are two points were future sales are discussed.

Firstly is the ten times sales, which is attributed to Luc, but does not specifically sale US only, it just says peak sales, doesnt even state a timeframe.

The second is a comment about $500mil sales in the US in 4-5years, but this doesnt seem to be attributed specifically to Luc in the article.

I might be wrong but it looks to me like jfm has combined those two separate comments to come up with what he wrote.

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities